Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Common Equity (2016 - 2026)

Heron Therapeutics filings provide 16 years of Common Equity readings, the most recent being $9.1 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 132.11% to $9.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.1 million, a 132.11% increase, with the full-year FY2025 number at $14.3 million, up 142.59% from a year prior.
  • Common Equity hit $9.1 million in Q1 2026 for Heron Therapeutics, down from $14.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $24.0 million in Q1 2022 to a low of -$40.0 million in Q3 2024.
  • Median Common Equity over the past 5 years was -$27.3 million (2025), compared with a mean of -$13.9 million.
  • Biggest five-year swings in Common Equity: plummeted 350.32% in 2023 and later soared 142.59% in 2025.
  • Heron Therapeutics' Common Equity stood at $13.6 million in 2022, then crashed by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then surged by 142.59% to $14.3 million in 2025, then plummeted by 36.25% to $9.1 million in 2026.
  • The last three reported values for Common Equity were $9.1 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025) per Business Quant data.